

This listing of claims will replace all prior versions, and listings, of claims in the application:

Please amend the claims as follows:

1. (Currently Amended) A therapeutically effective amount of bispecific [[antibody]] antibodies, wherein each bispecific antibody [[consisting]] consists essentially of two different antigen bindings sites, wherein the first antigen binding site specifically binds TRAIL receptor 1 and the second antigen binding site specifically binds TRAIL receptor 2, wherein the antibodies induce apoptosis in a target cell and wherein the target cell is a cancer cell or a virally-infected cell.
2. (Currently Amended) [[A]] The bispecific [[antibody]] antibodies of claim 1, wherein the antibody is a monoclonal antibody.
3. (Cancelled)
4. (Cancelled)
5. (Currently Amended) [[A]] The bispecific [[antibody]] antibodies of claim [[3]] 1, wherein the target cell is a virally-infected cell.
6. (Currently Amended) [[A]] The bispecific [[antibody]] antibodies of claim [[4]] 2, wherein the target cell is a virally-infected cell.
7. (Currently Amended) [[A]] The bispecific [[antibody]] antibodies of claim [[2]] 1, wherein the target cell is a cancer cell.
8. (Currently Amended) [[A]] The bispecific [[antibody]] antibodies of claim [[3]] 2, wherein the target cell is a cancer cell.
9. (Currently Amended) [[A]] The bispecific [[antibody]] antibodies of claim 7, wherein the cancer cell is selected from the group consisting of leukemia, lymphoma, melanoma, breast carcinoma, colon carcinoma, and colorectal cancer cells.
10. (Currently Amended) [[A]] The bispecific [[antibody]] antibodies of claim 8, wherein the cancer cell is selected from the group consisting of leukemia, lymphoma, melanoma, breast carcinoma, colon carcinoma, and colorectal cancer cells.
- 11 – 36. (Cancelled)